Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MTBVAC

Next Previous
Drug Profile

MTBVAC

Alternative Names: BBV-169 - Bharat biotech; MTBVAC 01

Latest Information Update: 03 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Zaragoza
  • Developer Bharat Biotech; Biofabri; Stellenbosch University; TuBerculosis Vaccine Initiative; University of Cape Town; University of Kwazulu Natal; University of Zaragoza
  • Class Attenuated vaccines; Tuberculosis vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Tuberculosis

Most Recent Events

  • 01 Mar 2025 Phase-II clinical trials in Tuberculosis (In adolescents, In adults, Prevention) in India (Intradermal) (NCT06997367)
  • 24 Mar 2024 Bharat Biotec plans a clinical trial in Tuberculosis (Prevention) in India (Intradermal) in 2025
  • 22 Feb 2024 University of Zaragoza in collaboration with International AIDS Vaccine Initiative and Biofabri plans a phase II trial for Tuberculosis (Prevention, In adolescents, In adults) (Intradermal), in September 2024 (NCT06272812)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top